Bayer initiates phase I study with SOS1 inhibitor, BAY3498264 in patients with advanced KRAS-mutated tumours: Berlin Saturday, December 14, 2024, 13:00 Hrs [IST] Bayer announced i ...

From a Hollywood star sharing an uplifting update to the death of a three-time boxing champion, here’s what’s happening in ...

IMA-203 is a gene-modified cell therapy commercialized by Immatics, with a leading Phase II program in Ovarian Cancer;Endometrial Cancer.

The FDA granted approval to nilotinib (Danziten) on November 14, 2024, for the treatment of adult patients with newly ...

3 Kirsten rat sarcoma (KRAS) is one of the most commonly mutated oncogenes in human cancer ... shows potential as a therapeutic agent for KRAS-mutant cancers, such as non-small cell lung cancer (NSCLC ...

Synovial sarcoma, according to the National Cancer Institute, is a cancer that typically formed in the tissue around joints in the arms or legs, and is commonly seen in children and young adults.